Category NEWS

AESARA

AESARA Names Denise Sánchez as Vice President of Regulatory Counsel and Compliance

AESARA Appoints Denise Sánchez as Vice President, Regulatory Counsel & Compliance Strategies AESARA, a leading Value & Access agency, announced that Denise Sánchez, JD, MS, MA, has joined the company as Vice President, Regulatory Counsel & Compliance Strategies. She served…

Read MoreAESARA Names Denise Sánchez as Vice President of Regulatory Counsel and Compliance
Estée

Indianapolis Community Unites to Take Action Against Breast Cancer at Susan G. Komen® MORE THAN PINK Walk

Breast Cancer Continues to Impact Communities; Indianapolis Rallies Together to Take Action at the Susan G. Komen® MORE THAN PINK Walk Susan G. Komen®, the world’s leading breast cancer organization, announced it will host the Indianapolis MORE THAN PINK Walk bringing together…

Read MoreIndianapolis Community Unites to Take Action Against Breast Cancer at Susan G. Komen® MORE THAN PINK Walk
Invivoscribe

Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems for High-Sensitivity MRD Testing

Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, announced that commercial shipments of the PrepQuant™ System have begun in North America. First…

Read MoreInvivoscribe Begins Commercial Shipments of PrepQuant™ Systems for High-Sensitivity MRD Testing
Gabrail Cancer

Gabrail Cancer Center Launches Study of Elranatamab and Low-Dose Lenalidomide Combination

The Gabrail Cancer Center Undertakes Investigator-Initiated Study Evaluating the T-Cell Engager Elranatamab in Combination with Starton Therapeutics’ Controlled Low-Dose Lenalidomide The Gabrail Cancer and Research Center, a PhaseWell Research site, announced that Nashat Gabrail, M.D., has received notification from the…

Read MoreGabrail Cancer Center Launches Study of Elranatamab and Low-Dose Lenalidomide Combination
Naturmega

Naturmega to Debut SUPRIAX2™ Solution in North America at SupplySide Global 2026

Naturmega’s SUPRIAX2™ Solution to Make Its North American Debut at SupplySide Global 2026 Naturmega, an advanced lipid science company specializing in omega-3 and next-generation lipid technologies, will introduce SUPRIAX2™ to the North American market at SupplySide Global 2026 in Las…

Read MoreNaturmega to Debut SUPRIAX2™ Solution in North America at SupplySide Global 2026
Yangi

Yangi Brings Cellera® Dry-Forming Technology to U.S. Converters Amid Tariff Changes

As Tariffs Reshape the Molded Fiber Market, Yangi Brings Its Dry-Forming Technology Cellera® to U.S. Converters Yangi, the Swedish developer of Cellera®, a dry-forming technology for fiber-based packaging, is entering the U.S. market with its quick-serve packaging range, as part of…

Read MoreYangi Brings Cellera® Dry-Forming Technology to U.S. Converters Amid Tariff Changes
Agenus

Agenus Reports Promising NEST Phase 2 Results Showing Deep Pathologic Responses in Resectable Colon Cancer

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer Agenus , a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase…

Read MoreAgenus Reports Promising NEST Phase 2 Results Showing Deep Pathologic Responses in Resectable Colon Cancer
Ivonescimab

Ivonescimab Plus Chemotherapy Shows Survival Benefit in Advanced Biliary Tract Cancer

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China Summit Therapeutics Inc. noted that its partner Akeso Inc. announced positive topline…

Read MoreIvonescimab Plus Chemotherapy Shows Survival Benefit in Advanced Biliary Tract Cancer